Physicians at the University of Illinois Hospital & Health Sciences System have developed a novel stem cell transplantation technique aimed at curing adults with sickle-cell anemia. Donor cells from a tissue-matched donor are transfused into the patient, producing healthy new blood cells and eliminating symptoms.
Previous studies have identified that bone marrow transplantation from a healthy donor could alleviate sickle cell disease, but chemotherapy is needed in these treatments to eliminate the patient’s own sickle cells. This new approach eliminates the need for chemotherapy, providing a more accessible and manageable prognosis for the 100,000 sickle cell patients in the United States alone and sharply limiting hospitalization time (and related costs). Dr. Damiano Rondelli, an author of the study explains, "Adults with sickle cell disease can be cured without chemotherapy - the main barrier that has stood in the way for them for so long. Our data provide more support that this therapy is safe and effective and prevents patients from living shortened lives, condemned to pain and progressive complications." And while this new treatment approach may still require identifying a tissue matching donor as it does not use autologous (the patient’s own) stem cells, patients must take immunosuppressant drugs following the treatment, the elimination of the need for chemotherapy represents a significant advance in the treatment of sickle cell anemia.
The University of Illinois Hospital’s research is an example of the potential for regenerative stem cell therapies to effectively treat seemingly intractable, historically incurable conditions. To learn more about stem cells and how to insure immediate access to emerging personalized regenerative treatments by banking your own valuable dental pulp stem cells, please visit StemSave or call 877-783-6728 (877- StemSave) today.
To view the full article, click here.
The Future of Regenerative Medicine is Now™.